BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30323751)

  • 1. Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis.
    Salati M; Baldessari C; Calabrese F; Rossi G; Pettorelli E; Grizzi G; Dominici M; Barbieri F
    Case Rep Oncol; 2018; 11(3):615-621. PubMed ID: 30323751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impressive response to nivolumab of non-small-cell lung cancer containing sarcomatoid components.
    Ota T; Niho S; Kirita K; Ishii G; Tsuboi M; Goto K
    Respirol Case Rep; 2019 Nov; 7(8):e00477. PubMed ID: 31452896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy.
    Anraku T; Hashidate H; Nakahara A; Imai T; Kawakami Y
    BMC Urol; 2023 Mar; 23(1):38. PubMed ID: 36934227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report.
    Chen P; Yu M; Zhang JL; Chen WY; Zhu L; Song Y; Jiang CY; Zhang S
    World J Clin Cases; 2020 Jul; 8(13):2876-2884. PubMed ID: 32742998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report.
    Jin C; Yang B
    Case Rep Oncol; 2020; 13(2):601-605. PubMed ID: 32595469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma.
    Gounant V; Brosseau S; Naltet C; Opsomer MA; Antoine M; Danel C; Khalil A; Cadranel J; Zalcman G
    Lung Cancer; 2016 Sep; 99():162-5. PubMed ID: 27565934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
    J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung.
    Roesel C; Kambartel K; Kopeika U; Berzins A; Voshaar T; Krbek T
    Curr Oncol; 2019 Apr; 26(2):e270-e273. PubMed ID: 31043837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment.
    Dai G; He L; Yan Q; Li Y; Huang Y; Li B; Wang G
    Front Oncol; 2023; 13():1167516. PubMed ID: 37456237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy.
    Sejima T; Masago T; Yoshida M; Nishi T; Kawabata Y; Tajima Y; Yumioka T; Honda M; Takenaka A
    Int Cancer Conf J; 2021 Oct; 10(4):285-289. PubMed ID: 34567939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report.
    Dionese M; Pierantoni F; Maruzzo M; Bimbatti D; Deppieri FM; Maran M; Gardiman MP; Basso U
    Anticancer Drugs; 2021 Feb; 32(2):222-225. PubMed ID: 32868643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient: A case report.
    Luo Y; Min L; Zhou Y; Tang F; Lu M; Xie H; Wang Y; Duan H; Zhang W; Tu C
    Medicine (Baltimore); 2021 Mar; 100(12):e25262. PubMed ID: 33761725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.
    Wu S; Wu S; Liao X; Zhou C; Qiu F; Wang C; Zhong W
    Front Immunol; 2023; 14():1274937. PubMed ID: 37936698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.
    Qian X; Wang Y; Liu F; Yuan Y; Fang C; Zhang X; Yuan S; Chen R; Yu B; Wang T; Yin Y; Li Y
    Front Immunol; 2022; 13():956982. PubMed ID: 36389780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
    George G; Schmidt L; Tolat P; Riese M; Kilari D
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diplopia Presenting in a Case of Pineal Metastasis of Pulmonary Sarcomatoid Carcinoma Refractory to Treatment.
    Mitsumasa A; Shinya N; Motoki O; Hirotaka K; Tadashi K
    Asian J Neurosurg; 2020; 15(2):449-454. PubMed ID: 32656152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the management of pulmonary sarcomatoid carcinoma.
    Shum E; Stuart M; Borczuk A; Wang F; Cheng H; Halmos B
    Expert Rev Respir Med; 2016 Apr; 10(4):407-416. PubMed ID: 26962707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
    Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
    Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage IV nonsmall cell lung cancer.
    Yin J; Dong J; Gao W; Wang Y
    Medicine (Baltimore); 2018 Nov; 97(44):e13112. PubMed ID: 30383701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
    Carbone DP; Ciuleanu TE; Schenker M; Cobo M; Bordenave S; Juan-Vidal O; Menezes J; Reinmuth N; Richardet E; Cheng Y; Mizutani H; Felip E; Zurawski B; Alexandru A; Paz-Ares L; Lu S; John T; Zhang X; Mahmood J; Hu N; De T; Santi I; Penrod JR; Yuan Y; Lee A; Reck M
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38346853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.